Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
Reads0
Chats0
TLDR
It is found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds ofospitalisation in patients with rheumatic disease.Abstract:
Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease. Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed. Results A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed. Conclusions We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.read more
Citations
More filters
Journal ArticleDOI
Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view.
Vasco C. Romão,I. Cordeiro,Carla Macieira,Filipa Oliveira-Ramos,José Carlos Romeu,Carlos Miranda Rosa,Saavedra Mj,Fernando Saraiva,Elsa Vieira-Sousa,João Eurico Fonseca +9 more
TL;DR: A practical approach is provided to tackle the nuances of rheumatology practice as restrictive measures are progressively lifted, while an effective vaccine is still pending and the need to reimpose the same strategy as further waves unfold is anticipated.
Journal ArticleDOI
Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt.
Nevin Hammam,Nevin Hammam,Samar Tharwat,Rawhya R. El Shereef,Ahmed M. Elsaman,Noha M. Khalil,Hanan M. Fathi,Mohamed Nabil Salem,Hanan M. El-Saadany,Nermeen Samy,Amany S. El-Bahnasawy,Yousra H Abdel-Fattah,Marwa A. Amer,Emad El-Shebini,Amira T El-Shanawany,Dina H. El-Hammady,Rasha A. Abdel Noor,Marwa Elkhalifa,Faten Ismail,Rasha M. Fawzy,Amany R. El-Najjar,Zahraa I. Selim,Nouran M. Abaza,Ahmed R. Radwan,Mervat IAbd Elazeem,Wael Abdel Mohsen,Abdelhafeez Moshrif,Eman F Mohamed,Loay I. Aglan,Soha H. Senara,Maha Emad Ibrahim,Iman Khalifa,Rasha El Owaidy,Noha El. Fakharany,Reem Hamdy A Mohammed,Tamer A. Gheita +35 more
TL;DR: In this paper, the authors explored the perspectives of Egyptian rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine and found that one third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it.
Journal ArticleDOI
COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
Sinem Nihal Esatoglu,Koray Tascilar,Hakan Babaoglu,Cemal Bes,Berna Yurttas,Servet Akar,Ozlem Pehlivan,Cansu Akleylek,Duygu Tecer,Emire Seyahi,Tuba Yuce-Inel,Nilufer Alpay-Kanitez,Erdal Bodakçi,Emre Tekgöz,Seda Colak,Ertugrul Cagri Bolek,Süleyman Serdar Koca,Umut Kalyoncu,Ozan Cemal Icacan,Serdal Ugurlu,H. E. Oz,Vedat Hamuryudan,Gulen Hatemi +22 more
TL;DR: Comorbidities and glucocorticoid use were associated with a worse outcome, while biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect.
Journal ArticleDOI
Ibuprofen and COVID-19 disease: separating the myths from facts.
TL;DR: In this paper, a literature search was conducted to evaluate ibuprofen's potential benefits and harms in the Coronavirus disease 2019 (COVID-19) poses novel challenges in the healthcare systems around the world.
Journal ArticleDOI
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection.
Allison Koenecke,Michael Powell,Ruoxuan Xiong,Zhu Shen,Nicole Fischer,Sakibul Huq,Adham M. Khalafallah,Marco Trevisan,Pär Sparén,Juan Jesus Carrero,Akihiko Nishimura,Brian Caffo,Elizabeth A. Stuart,Renyuan Bai,Verena Staedtke,David L. Thomas,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou,Chetan Bettegowda,Chetan Bettegowda,Maximilian F. Konig,Brett D. Mensh,Joshua T. Vogelstein,Susan Athey +25 more
TL;DR: In this paper, the alpha-1 adrenergic receptor (⍺1-AR) was used to prevent hyperinflammation and death in severe viral pneumonia, including Coronavirus disease 2019 (COVID-19).
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Journal ArticleDOI
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Related Papers (5)
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more